Novel Therapeutic Options in Patients with Type 2 Diabetes and high cardiovascular Risk

被引：0

作者：

Laubner, Katharina ^{[1
]}

Seufert, Jochen ^{[2
]}

机构：

[1] Univ Freiburg Klinikum, Klin Innere Med 2, Abt Endokrinol & Diabetol, Freiburg, Germany

[2] Univ Freiburg Klinikum, Klin Innere Med 2, Endokrinol & Diabetol, Freiburg, Germany

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2016年 / 141卷 / 11期

关键词：

MELLITUS;

D O I：

10.1055/s-0042-107747

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SGLT2 inhibitors represent a novel therapeutic approach for the tretment of type 2 diabetes mellitus. Beyond glucose control, these drugs also induce weight loss and blod pressure reduction. In a specific cardiovascular outcome trial (EMPA-REG-OUTCOME), the SGLT 2 inhibitor empagliflozin has for the first time demonstrated to reduce cardiovascular and overall mortality as well as hospitalization for heart failure in patients with type 2 diabetes and high cardiovascular risk. These results will drastically affect future recommendations for the treatment of type 2 diabetes mellitus.). © Georg Thieme Verlag KG ·Stuttgart · New York.

引用

页码：757 / 760

页数：4

共 50 条

[21] Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk
Nguyen, Elaine
Coleman, Craig I.
Nair, Suresh
Weeda, Erin R.
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2018, 32 (02) : 210 - 215
[22] High Risk Factors of Cardiovascular Diseases in Type 2 Diabetes
Srilatha, B.
JOURNAL OF DIABETES & METABOLISM, 2011, 2 (09)
[23] Tirzepatide Tested for Type 2 Diabetes With High Cardiovascular Risk
Slomski, Anita
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (24): : 2464 - 2464
[24] Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk
Duntas, Leonidas
Kolovou, Genovefa
FUTURE CARDIOLOGY, 2011, 7 (02) : 137 - 144
[25] Therapeutic options for the management of type 2 diabetes mellitus
Takiya, L
Chawla, S
AMERICAN JOURNAL OF MANAGED CARE, 2002, 8 (11): : 1009 - 1023
[26] Electrical changes during hypoglycaemia in patients with type 1 and type 2 diabetes and high cardiovascular risk
Mezquita-Raya, Pedro
Reyes-Garcia, Rebeca
de Torres-Sanchez, Alejandra
Gomez Matarin, Miguel
Cepero-Garcia, Daniel
Perez de Isla, Leopoldo
DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 138 : 44 - 46
[27] Comparison of different vascular risk engines in the identification of type 2 diabetes patients with high cardiovascular risk
Antonio Rodriguez-Poncelas
Gabriel Coll-de-Tuero
Marc Saez
José M. Garrido-Martín
José M. Millaruelo-Trillo
Joan Barrot de-la-Puente
Josep Franch-Nadal
BMC Cardiovascular Disorders, 15
[28] Comparison of different vascular risk engines in the identification of type 2 diabetes patients with high cardiovascular risk
Rodriguez-Poncelas, Antonio
Coll-de-Tuero, Gabriel
Saez, Marc
Garrido-Martin, Jose M.
Millaruelo-Trillo, Jose M.
Barrot de-la-Puente, Joan
Franch-Nadal, Josep
BMC CARDIOVASCULAR DISORDERS, 2015, 15
[29] Cardiovascular risk factors in patients with type 2 diabetes mellitus
Carolina Vintimilla, Evelin
Vintimilla Molina, Jhojana Rosati
Carmendel Rocio Parra
Martinez Santander, Diana Antonieta
Martinez Santander, Carlos Jose
del Rocio Andrade, Neida
Cumbe Guerrero, Karla Maria
Cardenas Heredia, Fredy Rosendo
REVISTA LATINOAMERICANA DE HIPERTENSION, 2018, 13 (04): : 356 - 360
[30] Attenuating cardiovascular risk factors in patients with type 2 diabetes
Garber, AJ
AMERICAN FAMILY PHYSICIAN, 2000, 62 (12) : 2633 - 2642

← 1 2 3 4 5 →